Sign in

Private company

BIORA THERAPEUTICS, INC.

BIORA THERAPEUTICS, INC. is a clinical-stage biotechnology company developing oral biotherapeutics.2 It is headquartered in San Diego, United States.2

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersSan Diego, United States2
  • Incorporated inDE3
  • Business address4330 La Jolla Village Drive, Suite 200, San Diego, Ca 921223
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI5493005XOS7E58D57T102
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O COGENCY GLOBAL INC., 19904 Dover, United States2
  • Registered withDivision of Corporations, Department of State, 50929232

See how the biggest companies compare on our leaderboards

Biora Therapeutics, Inc. is a clinical-stage biotechnology company developing oral biotherapeutics that could enable new treatment approaches in the delivery of therapeutics. Our pipeline includes two therapeutic delivery platforms:5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-1678575.0%Operating margin6
-3102875.0%Net margin6
-98.7%Revenue growth, 20236
-$48.6MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development39¢$29.8M
  • Selling, general and admin48¢$37.3M
  • Interest13¢$9.8M
  • Income tax0¢$90.0K

Out of $4.0K in revenue.6 The company lost money this year.

Financial statements

Revenue7896$4.0K in 2023−100% since 2019
0$50.0M$100.0M$150.0M2019: $144.0M$144.0M20192020: $162.0K$162.0K2020−100%2021: $1.2M$1.2M2021+670%2022: $305.0K$305.0K2022−76%2023: $4.0K$4.0K2023−99%
Gross profit78$1.2M in 2021−97% since 2019
0$20.0M$40.0M$60.0M2019: $43.5M$43.5M20192020: $162.0K$162.0K2020−100%2021: $1.2M$1.2M2021+670%
Operating income7896-$67.1M in 2023−52% since 2019
-$150.0M-$100.0M-$50.0M02019: -$140.1M-$140.1M20192020: -$107.6M-$107.6M2020−23%2021: -$117.8M-$117.8M2021+9%2022: -$61.8M-$61.8M2022−48%2023: -$67.1M-$67.1M2023+9%
Net income7896-$124.1M in 2023−16% since 2019
-$300.0M-$200.0M-$100.0M02019: -$148.0M-$148.0M20192020: -$192.5M-$192.5M2020+30%2021: -$247.4M-$247.4M2021+29%2022: -$38.2M-$38.2M2022−85%2023: -$124.1M-$124.1M2023+225%
Fiscal year201820192020202120222023
Revenue$144.0M7$162.0K8$1.2M9$305.0K6$4.0K6
Cost of revenue$100.5M7$08$08
Gross profit$43.5M7$162.0K8$1.2M8
Research and development$63.4M7$47.7M8$45.8M9$24.0M6$29.8M6
Selling, general and admin$73.3M9$38.0M6$37.3M6
Operating expenses$119.1M9$62.1M6$67.1M6
Operating income-$140.1M7-$107.6M8-$117.8M9-$61.8M6-$67.1M6
Interest$9.2M7$9.9M8$12.6M9$11.0M6$9.8M6
Income before tax-$178.6M9-$49.2M6-$124.4M6
Income tax-$706.0K7-$37.5M8-$119.0K9-$420.0K6-$90.0K6
Net income-$148.0M7-$192.5M8-$247.4M9-$38.2M6-$124.1M6
Earnings per share-$64.339-$5.006-$7.876
Earnings per share (diluted)-$64.339-$5.006-$7.876
Shares (weighted, basic)3.8M shares97.6M shares615.8M shares6
Shares (weighted, diluted)3.8M shares97.6M shares615.8M shares6

Compare BIORA THERAPEUTICS, INC. with another company

Corporate structure

BIORA THERAPEUTICS, INC. sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of BIORA THERAPEUTICS, INC.

  • BIORA THERAPEUTICS, INC. San Diego, California, United States
    • Biora Therapeutics UK Limited, a private limited company incorporated in Subsidiary · United Kingdom

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What BIORA THERAPEUTICS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.3M6 Dec 31, 2023$5.7M6 Dec 31, 2022−42.3%
Accumulated depreciation$2.1M6 Dec 31, 2023$4.0M6 Dec 31, 2022−47.3%
Property and equipment, net$1.2M6 Dec 31, 2023$1.7M6 Dec 31, 2022−30.1%
Operating-lease assets (leased space)$1.6M6 Dec 31, 2023$1.5M6 Dec 31, 2022+8.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$15.0M6 Dec 31, 2023$30.5M9 Dec 31, 2022−50.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$6.1M6 Dec 31, 2023$6.1M6 Dec 31, 20220%

Leadership

Who has led BIORA THERAPEUTICS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Harry Stylli2020–2021
  2. Aditya P. Mohanty2021–2024

Chair

  1. Harry Stylli2020–2021

Chief financial officer

  1. Eric Desparbes2020–2024

Chief operating officer

  1. Damon Silvestry2020–2021
2025
Board members and other officers (16)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Biora Therapeutics UK Limited, a private limited company incorporated in the United Kingdom4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • PROGENITY, INC.Jun 17, 2015 to Apr 19, 20223
  • ASCENDANT MDX, INC.Jun 27, 2013 to Jun 28, 20133

Timeline

  1. Dec 30, 20248-K Entered a material agreement; Bankruptcy or receivership; Debt or obligation accelerated31
  2. Dec 10, 20248-K Listing notice or transfer32
  3. Nov 15, 20248-K Listing notice or transfer; Executive or director change; Shareholder vote33
  4. Nov 14, 20248-K Results of operations34
  5. Oct 29, 20248-K Entered a material agreement; Unregistered sale of shares35
  6. Oct 11, 20248-K Change to shareholders' rights; Bylaws or fiscal year changed; Shareholder vote36
  7. Oct 7, 20248-K New debt or obligation; Unregistered sale of shares37
  8. Sep 13, 20248-K New debt or obligation; Unregistered sale of shares38
  9. Sep 5, 20248-K Other events39
  10. Aug 21, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares40
  11. Aug 12, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares41
  12. Aug 12, 20248-K Results of operations42
  13. Nov 15, 2021New chief executive Aditya P. Mohanty becomes CEO12
  14. Jun 18, 2020New chief executive Harry Stylli becomes CEO13
  15. Jan 9, 2012Founded BIORA THERAPEUTICS, INC. is founded2

Calendar

When it reported results

  1. Nov 14, 2024Reported quarterly or annual results34
  2. Aug 12, 2024Reported quarterly or annual results42
  3. May 15, 2024Reported quarterly or annual results43
  4. Mar 26, 2024Reported quarterly or annual results44
  5. Nov 13, 2023Reported quarterly or annual results45
  6. Aug 14, 2023Reported quarterly or annual results46
  7. May 15, 2023Reported quarterly or annual results47
  8. Mar 30, 2023Reported quarterly or annual results48

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

238 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 64 major events, 68 insider forms, 21 large holders, 72 other. The latest 20:

  1. Aug 4, 2025SCHEDULE 13G EDGAR
  2. Aug 4, 2025SCHEDULE 13G/A EDGAR
  3. Jul 10, 2025SCHEDULE 13G/A EDGAR
  4. Mar 26, 2025SCHEDULE 13D/A EDGAR
  5. Dec 30, 20248-K CURRENT REPORT EDGAR
  6. Dec 16, 20244 EDGAR
  7. Dec 10, 20248-K EDGAR
  8. Nov 15, 20248-K EDGAR
  9. Nov 14, 202410-Q EDGAR
  10. Nov 14, 20248-K EDGAR
  11. Nov 14, 2024SC 13G EDGAR
  12. Oct 29, 20248-K EDGAR
  13. Oct 29, 2024424B5 EDGAR
  14. Oct 29, 2024424B3 EDGAR
  15. Oct 29, 2024424B3 EDGAR
  16. Oct 29, 2024424B3 EDGAR
  17. Oct 29, 2024424B3 EDGAR
  18. Oct 29, 2024424B3 EDGAR
  19. Oct 23, 2024DEF 14A EDGAR
  20. Oct 11, 2024PRE 14A EDGAR

The 238 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 1 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 9, 2022Athyrium Opportunities 2020 LPDirectorBuy12,506,250Form 4
Jul 5, 2022Sarna SurbhiDirectorSale7,517$0.61$4.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2023Adi Mohanty$574.1K$3.1M57
2023Eric d’Esparbes$500.8K$1.6M57
2023Clarke Neumann$483.0K$1.5M57
2022Chief Executive Officer$550.0K$3.5M57
2022Chief Financial Officer$486.1K$1.7M57
2022SVPGeneral Counsel and Secretary$464.6K$1.5M57

SEC filer profile

How BIORA THERAPEUTICS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBIORA THERAPEUTICS, INC.1
  • CIK0001580063
  • Employer ID (EIN)27-39503901
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address4330 La Jolla Village Drive, Suite 200, San Diego, CA 921221
  • Phone855-293-26391
  • Shares outstanding4,522,702 as of Nov 6, 202411
  • Public float$39.0M as of Jun 30, 20236
  • On EDGAR sinceJun 27, 20131
  • Filings428 in all: 4 (137), 8-K (83), 424B5 (22), 3 (19), CORRESP (17), UPLOAD (15), 10-Q (14), SC 13D/A (14)1
    All 39 form types

    EFFECT (11), 424B3 (8), D (7), DEF 14A (7), S-3 (7), DEFA14A (6), S-1/A (5), 10-K (4), 3/A (4), DRS/A (4), PRE 14A (4), S-1 (4), SC 13G (4), S-8 (3), 424B4 (2), ARS (2), D/A (2), DEF 14C (2), DRS (2), DRSLTR (2), FWP (2), SC 13D (2), SC 13G/A (2), SCHEDULE 13G (2), SCHEDULE 13G/A (2), SEC STAFF LETTER (2), 25-NSE (1), 4/A (1), 8-A12B (1), CERT (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Apr 1, 2024
    Quarterly report (10-Q) Nov 14, 2024
    Proxy statement (DEF 14A) Oct 23, 2024
    Latest 8-K (8-K) Dec 30, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57